PDS Biotechnology (NASDAQ:PDSB) Downgraded to Sell at StockNews.com

StockNews.com lowered shares of PDS Biotechnology (NASDAQ:PDSBFree Report) from a hold rating to a sell rating in a research note issued to investors on Saturday.

Separately, Cantor Fitzgerald restated an overweight rating on shares of PDS Biotechnology in a report on Friday, January 12th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus target price of $17.67.

Get Our Latest Report on PDS Biotechnology

PDS Biotechnology Stock Performance

PDSB opened at $4.69 on Friday. The company has a current ratio of 6.21, a quick ratio of 6.21 and a debt-to-equity ratio of 0.96. PDS Biotechnology has a twelve month low of $3.80 and a twelve month high of $10.27. The business’s 50 day moving average is $5.23 and its 200-day moving average is $5.15. The stock has a market cap of $145.91 million, a PE ratio of -2.74 and a beta of 1.72.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PDSB. BlackRock Inc. lifted its holdings in PDS Biotechnology by 276.6% in the 2nd quarter. BlackRock Inc. now owns 1,732,918 shares of the company’s stock valued at $8,717,000 after purchasing an additional 1,272,801 shares in the last quarter. Vanguard Group Inc. lifted its holdings in PDS Biotechnology by 5.0% in the third quarter. Vanguard Group Inc. now owns 1,148,078 shares of the company’s stock valued at $3,410,000 after acquiring an additional 54,193 shares during the period. Renaissance Technologies LLC increased its position in PDS Biotechnology by 49.5% during the 1st quarter. Renaissance Technologies LLC now owns 665,037 shares of the company’s stock valued at $4,117,000 after buying an additional 220,300 shares in the last quarter. Two Sigma Investments LP boosted its position in shares of PDS Biotechnology by 18.6% during the first quarter. Two Sigma Investments LP now owns 589,050 shares of the company’s stock worth $3,623,000 after buying an additional 92,581 shares during the period. Finally, Two Sigma Advisers LP raised its holdings in PDS Biotechnology by 4.5% in the 1st quarter. Two Sigma Advisers LP now owns 584,400 shares of the company’s stock valued at $3,594,000 after acquiring an additional 25,200 shares during the last quarter. Institutional investors own 25.78% of the company’s stock.

PDS Biotechnology Company Profile

(Get Free Report)

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.

Read More

Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.